Recovery · Reference
ARA-290 for Men: What the Research Has Looked At, and What It Is Not
This page covers what ARA-290 is, what research has and has not looked at, the questions men ask most often (EPO, testosterone, training, TRT, sport), what a physician rules out first, and how Pepti supplies it. The general reference is what is ARA-290, and the trial-by-trial detail is in ARA-290 benefits.
Treatments mentioned
ARA-290 has not been studied in men specifically: its randomised phase 2 trials enrolled adults with sarcoidosis-associated small-fibre neuropathy or type 2 diabetes with painful neuropathy, and none in the live research reports results separately for men. Those trials reported improved neuropathy symptom questionnaires and increased corneal nerve fibre density after four weeks, but pain-intensity scores did not clearly separate from placebo. ARA-290 is built from a piece of erythropoietin yet does not raise red cell counts, and it is not a testosterone booster, a performance compound or a recovery peptide for muscle and tendon. It is a compounded prescription injection and is not FDA approved.
This page covers what ARA-290 is, what research has and has not looked at, the questions men ask most often (EPO, testosterone, training, TRT, sport), what a physician rules out first, and how Pepti supplies it. The general reference is what is ARA-290, and the trial-by-trial detail is in ARA-290 benefits.
ARA-290 for Men
The short answer
| Question | What the live research shows | Strength of evidence |
|---|---|---|
| Has it been studied in men specifically? | No trial in the live research reports men separately | None |
| Small-fibre neuropathy in sarcoidosis | Trials in 2012, 2013 and 2017 (up to 64 people) | Human, small, short, developer-run |
| Painful neuropathy in type 2 diabetes | One 2015 phase 2 trial, 28 days | Human, small, not replicated |
| Does it raise red cell counts like EPO? | No; engineered not to, and the trials confirmed it | Human |
| Does it raise testosterone? | It is not a hormone and not described to act on any hormone axis | Not a testosterone booster |
| Muscle, tendon or training recovery | No human data for musculoskeletal injury | None |
| Alongside TRT | No study of the combination | None |
| Tested sport | Named as a prohibited peptide in the anti-doping literature | Not an option for tested athletes |
ARA-290 for Men
What ARA-290 is, in one paragraph
ARA-290, also called cibinetide and in older papers helix B surface peptide, is an eleven-amino-acid peptide whose sequence was lifted from one helix of erythropoietin, the kidney hormone that tells bone marrow to make red blood cells. A 2008 paper in the Proceedings of the National Academy of Sciences introduced it as a "nonerythropoietic, tissue-protective" peptide: the idea was to keep the part of erythropoietin that appears to protect tissue and leave behind the part that raises red cell counts. It is described as engaging the innate repair receptor, which pairs one erythropoietin receptor with the beta-common receptor (CD131) and is described as switched on in injured or inflamed tissue. It is not a painkiller, not a hormone and not a growth hormone secretagogue.
ARA-290 for Men
What research has looked at
| Trial | Who | Route and length | What it reported |
|---|---|---|---|
| Molecular Medicine, 2012, pilot | 22 people with sarcoidosis and small-fibre neuropathy symptoms | Intravenous, three times a week, four weeks | Symptom questionnaire improved more than placebo; pain score and fatigue improved equally in both groups |
| Molecular Medicine, 2013 | People with sarcoidosis and documented small nerve fibre loss | Daily subcutaneous, 28 days | Symptoms improved; corneal nerve fibre density and six-minute walk distance increased |
| Molecular Medicine, 2015 | People with type 2 diabetes and painful neuropathy | Daily subcutaneous, 28 days, plus a month of follow-up | PainDetect scores improved; HbA1c and lipids improved against placebo |
| Investigative Ophthalmology and Visual Science, 2017 | 64 people with sarcoidosis-associated nerve fibre loss | Placebo or one of three daily doses, 28 days | Only the middle dose beat placebo on corneal nerve fibre area; pain reduction not statistically significant |
What it shows. A consistent signal on small nerve fibre regrowth and neuropathy symptom questionnaires in two specific patient groups, with a clean safety record over four-week courses.
What it does not show. Any result reported by sex, any benefit in a healthy man, any effect on pain intensity clearly beyond placebo, or anything beyond four weeks of treatment. No phase 3 trial has been completed.
ARA-290 for Men
What changes for men
It is not EPO, and not a blood-doping agent
This is the first thing many men, especially endurance athletes, ask. ARA-290 comes from erythropoietin's structure, but it does not bind the erythropoietin receptor pair that drives red cell production, so it does not raise haemoglobin, and the trials confirmed no effect on blood counts. It will not do what EPO does for oxygen delivery. That also means it does not carry erythropoietin's clotting risk. It is still a prohibited peptide in sport, covered below.
It is not a testosterone booster
ARA-290 is not described to act on testosterone, the pituitary or any hormone axis. If low testosterone is the real question, peptides for testosterone covers what has and has not been studied.
It is not a muscle or tendon recovery peptide
ARA-290 sits in Pepti's Recovery category, which causes confusion. Its research is in nerve tissue: small nerve fibres that carry pain and temperature. It has no human data for musculoskeletal injury. A tendon, ligament or muscle problem is where BPC-157, TB-500 or the BPC-157 + TB-500 stack are usually discussed. Burning, tingling and numbness from small nerve fibre damage is the ARA-290 conversation.
Alongside testosterone therapy
No study has looked at ARA-290 alongside testosterone replacement, and no interaction is described, but ARA-290 has no established interaction list at all. List your testosterone prescription and whoever manages it on your intake so your physician can review them together. See can you take peptides with testosterone.
Diabetes and glucose-lowering medication
One of ARA-290's two trial populations was people with type 2 diabetes and painful neuropathy. Because the 2015 trial reported improved HbA1c, anyone on insulin or other glucose-lowering medication should tell their physician. Glucose control is the foundation of diabetic neuropathy care, and semaglutide and tirzepatide have large human trials for glucose and weight, which ARA-290 does not. The combination is covered in can you take ARA-290 with tirzepatide.
Fertility
Nothing in the live research looks at ARA-290 and male fertility in either direction. If conception is a goal, raise it with your physician before starting. See do peptides affect fertility.
Tested sport
ARA-290 is specifically named as a prohibited peptide in the anti-doping literature, and detection methods for it have been published. A prescription does not create an exemption. The detail is in is ARA-290 banned in sports.
ARA-290 for Men
What a physician rules out first
Small-fibre neuropathy has testable causes, and they come before a peptide.
| Possible cause | How it can show up | Why it comes first |
|---|---|---|
| Poorly controlled glucose or early type 2 diabetes | Burning or numb feet, thirst, central weight | Glucose control is the foundation of care |
| B12 deficiency | Tingling, numbness, fatigue | Findable and directly treatable; methylcobalamin is the more direct conversation |
| Thyroid disease | Fatigue, weight change, cold intolerance | Common, findable, not treated by a peptide |
| A soft-tissue injury rather than nerve damage | Pain tied to one joint or tendon | A different set of peptides is discussed |
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. More is in peptides for men over 40.
ARA-290 for Men
Side effects
Nothing in the live research suggests the profile differs between men and women.
| What is reported or relevant | When | What to do |
|---|---|---|
| Injection-site redness, mild soreness, occasional bruising | Any time | Rotate sites |
| Signs that could be low blood sugar, if you take glucose-lowering medication | Any time | Treat it first, then tell your care team |
| Facial or throat swelling, trouble breathing, widespread rash | Rare | Call 911 first, then tell your physician |
Across the trials, investigators reported no safety concerns from clinical or laboratory assessments, and a twelve-week study found no antibodies against the peptide. Long-term data does not exist. The full detail is in ARA-290 side effects.
ARA-290 for Men
Where ARA-290 stands with the FDA
As of the FDA's 14 May 2026 update, cibinetide (ARA-290) is in Category 3 of substances nominated for the 503A bulks list, "Bulk Drug Substances Nominated Without Adequate Support." That is a paperwork category, not a safety finding. It is not on the Category 2 list of substances that raise significant safety risks, and it was not among the peptides the Pharmacy Compounding Advisory Committee discussed in July 2026. It is prescription-only, compounded, and not FDA approved.
ARA-290 for Men
How Pepti supplies ARA-290
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| ARA-290 | 5 mL multi-dose vial, 2 mg/mL (10 mg ARA-290) | 0.25 mL (25 units) subcutaneously once daily Monday through Friday; 0.5 mg per dose, 20 doses | $219/mo |
Twenty weekday doses is about four weeks, which matches the treatment length the human trials studied; refills run every 28 days, one vial per fill. The arithmetic is in ARA-290 dosage. Your physician sets your directions after reviewing your intake, and they are printed on the vial.
The price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. The vial arrives as a ready-to-use multi-dose solution with sterile syringes and alcohol prep pads, shipped refrigerated with ice packs.
ARA-290 for Men
Where to get ARA-290 prescribed
ARA-290 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, your medications (including any testosterone or glucose-lowering medication), whether you are drug tested, and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your care team stays reachable for questions and side effects.
Step by step: how to get ARA-290 prescribed online.
References
What this is based on.
References
- Dahan A, Dunne A, Swartjes M et al.. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density · Mol Med (2013) · PMID 24136731
- Heij L, Niesters M, Swartjes M et al.. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study · Mol Med (2012) · PMID 23168581
- Brines M, Patel NS, Villa P et al.. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin · Proc Natl Acad Sci U S A (2008) · PMID 18676614
- Swartjes M, Morariu A, Niesters M et al.. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice · Anesthesiology (2011) · PMID 21873879
- Swartjes M, van Velzen M, Niesters M et al.. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response · Mol Pain (2014) · PMID 24529189
- van Velzen M, Heij L, Niesters M et al.. ARA 290 for treatment of small fiber neuropathy in sarcoidosis · Expert Opin Investig Drugs (2014) · PMID 24555851
- Brines M, Dunne AN, van Velzen M et al.. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes · Mol Med (2015) · PMID 25387363
- Cerit H, Veer IM, Dahan A et al.. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action · Eur Neuropsychopharmacol (2015) · PMID 26431906
- Dahan A, Brines M, Niesters M et al.. Targeting the innate repair receptor to treat neuropathy · Pain Rep (2016) · PMID 29392190
- Culver DA, Dahan A, Bajorunas D et al.. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain · Invest Ophthalmol Vis Sci (2017) · PMID 28475703
- Thomas A, Knoop A, Schänzer W et al.. Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports · Drug Test Anal (2017) · PMID 28941172
- Brines M, Culver DA, Ferdousi M et al.. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy · Sci Rep (2018) · PMID 29549285
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
ARA-290 for Men, answered.
It has not been studied in men specifically. Its trials were in adults with sarcoidosis or type 2 diabetes and small-fibre neuropathy, and none reports men separately. There are no trials in healthy men.
No. It was built from a piece of erythropoietin but engineered not to bind the receptor pair that drives red cell production, and the trials confirmed no effect on blood counts.
No. It is not a hormone and is not described to act on testosterone or any hormone axis.
It has no human data for musculoskeletal injury. Its research is in small nerve fibres. Tendon and muscle problems are where BPC-157 and TB-500 are usually discussed.
No interaction is described, but no study has looked at the combination. List your testosterone prescription and whoever manages it on your intake.
One 2015 trial in type 2 diabetes reported improved neuropathy symptom scores and HbA1c over 28 days. It was small and not replicated, and pain intensity did not clearly separate from placebo across the trials. Glucose control comes first.
Yes. It is named as a prohibited peptide in the anti-doping literature, and detection methods have been published. A prescription does not exempt you.
The same as for anyone: mostly injection-site redness, soreness or bruising. The trials reported no safety concerns. Facial or throat swelling or trouble breathing needs 911.
At Pepti, ARA-290 is $219 a month, all-in, covering medication, physician review, refill management and shipping.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.